BridgeBio Pharma Inc

In a Stage 2 advance within a long-term uptrend, BBIO retains a bullish medium-term bias. Recent price parabolic spike was followed by a healthy pullback into rising 9/21 EMAs, presenting a favorable entry zone. Volume remains supportive with lighter pullback volume, and no active reversal patterns are present. Despite moderate transition risk signaled by RSI divergence and a distribution day, short-term conditions support buying on this pullback.

• ↑Atruvi generated $180.6 M in Q1’26, up 392% YoY with 6,100+ patient starts
• ↑Upcoming rare-disease launches (LGMD2I, ADH1, Infigratinib) target underserved markets
• ↓Operating expenses rose to $290.5 M in Q1’26, risking cash burn if growth falters